Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


*Certain sections in the report may be removed or altered based on the availability and relevance of data.

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase

* Global Markets Direct, is a research brand owned and operated by GlobalData.


  • The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

  • The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects
  • The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

AbbVie Inc
AbVacc Inc
Acticule Life Sciences Ltd
Acurx Pharmaceuticals Inc
AEON Medix Inc
AimMax Therapeutics Inc
AlphaMab Co Ltd
Amicrobe Inc
Amprologix Ltd
Andira Pharmaceuticals
AnyGen Co Ltd
Aphios Corp
Aridis Pharmaceuticals Inc
Arietis Corp
Arizona State University
Aurigene Oncology Ltd
aVaxziPen Limited
Basilea Pharmaceutica Ltd
Bharat Biotech Ltd
Biocidium Biopharmaceuticals Inc
Biological Mimetics Inc
Biomendics LLC
BioPlx Microbiomics Pvt Ltd
Bioseka UAB
Bioversys AG
Botanix Pharmaceuticals Ltd
Cantab Anti-infectives Ltd
Catholic University of Korea
Cellics Therapeutics Inc
Centivax Inc
Chengdu Olymvax Biopharmaceuticals Inc
China Agricultural University
Chinese Academy of Medical Sciences and Peking Union Medical College
Crestone Inc
CrystalGenomics Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Debiopharm International SA
DeNovaMed Inc
Destiny Pharma Plc
Eagle Pharmaceuticals Inc
East China University Of Science And Technology
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Evoq Nano Inc
Exbaq LLC
Georgia State University
Global BioLife Inc Ltd
H. Lee Moffitt Cancer Center & Research Institute Inc
Harvard Medical School
Harvard University
Helmholtz Centre for Infection Research
Helperby Therapeutics Group Ltd
Hsiri Therapeutics LLC
HyPharm GmbH
ImmunArtes LLC
Immupharma Plc
Inimmune Corp
Integrated BioTherapeutics Inc
ioGenetics Inc
Jawaharlal Nehru Centre for Advanced Scientific Research
Jilin University
Johns Hopkins University
Johnson & Johnson
KBP Biosciences Co Ltd
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lysimmune BioScience
Lyticon LLC
Madam Therapeutics BV
Matrisys Bioscience Inc
Meiji Seika Pharma Co Ltd
MGB Biopharma Ltd
Microbiotix Inc
MicuRx Pharmaceuticals Inc
Nanyang Technological University
National Taiwan University
NES Biotechnology Co Ltd
Northeastern University
Novalex Therapeutics Inc
NovoBiotic Pharmaceuticals LLC
NYU Robert I. Grossman School of Medicine
Olgram SAS
Opal Biosciences Ltd
Oppilotech Ltd
Oragenics Inc
Oryn Therapeutics
Oxford Drug Design Ltd
Palacky University Olomouc
Paris Descartes University
Phico Therapeutics Ltd
Prokaryotics Inc
Prommune Inc
Purdue University
Pusan National University
Q2 Pharma Ltd
Quratis Inc
QureTech Bio AB
Recce Pharmaceuticals Ltd
Rice University
Rockefeller University
Sano Chemicals Inc
Scandion Oncology AS
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai High-Tech Bioengineering Co Ltd
Shanghai MengKe Pharmaceuticals Inc
Shanghai Shangyao Xinya Pharmaceutical Co Ltd
Shanghai Space Peptides Pharmaceutical Co Ltd
smartbax GmbH
Sorrento Therapeutics Inc
Stony Brook University
Swansea University
TaeJoon Pharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TAXIS Pharmaceuticals Inc
Technical University of Munich
Telum Therapeutics SL
TGV-Inhalonix Inc
The Lundquist Institute
The University of British Columbia
Theralia AB
Therapeutic Systems Research Laboratories Inc
Trellis Bioscience LLC
University of California Los Angeles
University of California San Diego
University of Illinois
University of Lincoln
University of Miami
University of Nebraska Medical Center
University of North Texas Health Science Center
University of Notre Dame
University of Oklahoma
University of Pittsburgh
University of Queensland
University of South Florida
University of Southern Denmark
University of Strasbourg
University of Tennessee Research Foundation
University of Wisconsin Madison
University of Wisconsin-La Crosse
Vanderbilt University
Venomyx Inc
Viosera Therapeutics
Virginia Polytechnic Institute and State University
Vitas Pharma Research Pvt Ltd
VLP Biotech Inc
Wayne State University
Wockhardt Ltd
Wuhan University
Yale University
Yungjin Pharm Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023 in real time.

  • Access a live Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.